LLY Q2 Revenue Surges 48% to $23B, Retatrutide BLA Set for Q1 2027

Eli Lilly (LLY) reported Q2 2026 revenue of $22.97 billion, up 48% year over year, crushing estimates. The company raised full-year revenue guidance to $86 billion and disclosed that the retatrutide Phase 3 clinical data package is complete, with a BLA filing planned for Q1 2027. LLY closed at $1,157.93 with a market cap of $995 billion.

The numbers

• Revenue: $22.97 billion (+48% YoY)
• Mounjaro: $9.9 billion (+91%)
• Zepbound: $4.9 billion
• FY guidance: Raised to $86 billion
• Obesity franchise quarterly revenue: $14.8 billion (Mounjaro + Zepbound)
• Retatrutide: Phase 3 complete, BLA filing Q1 2027
• Foundayo (orforglipron): Approved April 2026, ramping

What the numbers mean

Lilly’s obesity franchise is generating $14.8 billion per quarter from Mounjaro and Zepbound alone. At an $86 billion annual revenue run rate, Lilly is on track to become the world’s largest pharma company by revenue. This was the fourth consecutive quarter of upward guidance revisions, signaling that GLP-1 demand is still accelerating, not plateauing.

The real story is not the earnings beat. It is the retatrutide timeline acceleration. With the complete Phase 3 package and a pre-approval access program now live, retatrutide could reach the market by mid-2027. The triple agonist (GLP-1/GIP/glucagon) has shown 26.6% placebo-adjusted weight loss and a 75% reduction in knee osteoarthritis pain. That efficacy approaches bariatric surgery levels.

The pre-approval access program is an aggressive move. It puts retatrutide in patients’ hands before FDA approval, builds real-world evidence, and applies competitive pressure on Novo Nordisk’s CagriSema, which has yet to report Phase 3 data. For context on the broader GLP-1 competitive dynamic, see our GLP-1 obesity market analysis.

Foundayo establishes the oral market

Foundayo (orforglipron), the only oral GLP-1 with no food or water restrictions, was approved in April 2026 and is now establishing the oral obesity market ahead of Novo Nordisk’s oral semaglutide. An oral GLP-1 that works without dosing restrictions is a meaningful convenience advance. The combination of Foundayo (oral daily) and retatrutide (injectable, monthly or less) gives Lilly three distinct obesity products targeting different patient segments.

Risk to watch

The specific risk is manufacturing capacity. Can Lilly produce enough supply for three blockbuster obesity drugs simultaneously? Mounjaro and Zepbound have already faced periodic shortages. Adding retatrutide to the production queue without adequate capacity planning could limit the launch trajectory. The pre-approval access program helps build supply data, but the real test comes at commercial launch.

Source: Eli Lilly Q2 2026 financial results